In a patient with a 4 cm left ventricular thrombus on echocardiogram and an ejection fraction of 20‑25%, who after three months of guideline‑directed medical therapy and apixaban (Eliquis) still has an ejection fraction <35% and persistent thrombus, can a transvenous implantable cardioverter‑defibrillator be placed, or must a subcutaneous ICD be used?

Can You Place a Transvenous ICD with Persistent LV Thrombus?

You can proceed with a transvenous ICD placement in this patient with persistent LV thrombus, but a subcutaneous ICD (S-ICD) should be strongly considered as the preferred option to avoid the risk of dislodging the thrombus during lead placement and causing systemic embolization.

Primary Consideration: Risk of Embolization

The fundamental concern with transvenous ICD placement in the presence of a 4 cm LV thrombus is the mechanical risk during lead manipulation. When advancing a transvenous lead through the right heart and positioning it in the right ventricle, there is theoretically minimal direct contact with a left ventricular thrombus. However, the real risks include:

• Hemodynamic changes during the procedure that could dislodge the thrombus
• Arrhythmias induced during lead positioning that alter flow dynamics
• Paradoxical embolization if any right-sided thrombus forms or if there's an undetected patent foramen ovale

The Subcutaneous ICD Advantage

The 2017 AHA/ACC/HRS guidelines 1 specifically highlight that the S-ICD was designed to avoid venous access complications and is particularly valuable in certain high-risk scenarios. Key points include:

• No intracardiac hardware: The S-ICD eliminates any risk of mechanical interaction with the LV thrombus since no leads traverse the venous system or cardiac chambers
• Lower infection risk: The S-ICD has lower infection rates compared to transvenous systems, which is relevant since this patient will require continued anticoagulation 1
• Effective defibrillation: Studies show >90% first-shock conversion efficacy for VF and 100% overall conversion success 1

Critical Limitations to Consider

Before choosing S-ICD, you must address these requirements:

The patient MUST pass ECG screening to ensure adequate sensing with the S-ICD system 1. This is non-negotiable and must be performed pre-implantation.

The S-ICD cannot provide:

• Antitachycardia pacing (ATP) for VT termination
• Bradycardia pacing support
• Cardiac resynchronization therapy (CRT) if needed

Given this patient's EF remains 20-25%, if there's any consideration for future CRT upgrade (which would be indicated), this complicates the decision. However, with EF still <35% at 3 months, the patient clearly meets criteria for ICD therapy for primary prevention.

The Anticoagulation Concern

The persistent thrombus despite 3 months of apixaban raises a red flag. Recent case reports 2, 3 document LV thrombus progression or recurrence on apixaban therapy. While the FDA label 4 approves apixaban for various thrombotic conditions, LV thrombus is not an FDA-approved indication, and warfarin remains the evidence-based standard for this indication.

Before any ICD placement, consider:

• Switching from apixaban to warfarin with target INR 2.0-3.0
• Reassessing thrombus burden with cardiac MRI for better characterization
• Ensuring medication adherence (a common cause of treatment failure 3)

Practical Algorithm for Decision-Making

Step 1: Verify the patient needs pacing or ATP

• If yes (bradycardia, symptomatic VT requiring ATP) → Must use transvenous ICD despite thrombus risk
• If no → Proceed to Step 2

Step 2: Perform S-ICD ECG screening

• If passes screening → S-ICD is preferred to avoid thrombus interaction risk
• If fails screening → Must use transvenous ICD

Step 3: If transvenous ICD is required:

• Optimize anticoagulation (consider switching to warfarin)
• Obtain cardiac MRI to assess thrombus mobility and characteristics
• Consider delaying procedure if thrombus appears mobile or pedunculated
• Use fluoroscopy and echocardiographic guidance during lead placement
• Minimize procedure time and lead manipulation

Step 4: Peri-procedural anticoagulation management

• Continue anticoagulation through the procedure if using S-ICD (minimal bleeding risk)
• For transvenous ICD, balance bleeding risk with thrombotic risk—consider holding anticoagulation for 24 hours pre-procedure per FDA guidance 4, but this must be individualized given the large persistent thrombus

Common Pitfalls

• Assuming DOACs are equivalent to warfarin for LV thrombus: They are not FDA-approved for this indication, and failure rates are documented 2, 3
• Not performing S-ICD screening: This is mandatory and some patients will fail 1
• Ignoring the need for pacing: If the patient develops bradycardia or needs CRT, S-ICD is not an option
• Proceeding without optimizing anticoagulation first: A persistent 4 cm thrombus after 3 months suggests inadequate treatment

In this specific case, the S-ICD is the safer choice if the patient passes screening and doesn't require pacing capabilities, as it completely eliminates the risk of mechanical thrombus disruption during device implantation.